NDA 020220 · Bayer Hlthcare
Ultravist 150
Iopromide · Injection · Radiographic Contrast Agent
NovelLast checked: Nov 20, 2026Latest source record: Jun 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
May 10, 1995
Approved uses
4
Original approval plus efficacy supplements
Registered trials
8
1 Phase 3, 0 recruiting
FAERS reports
4,182
3,709 serious, 336 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NOT FOR INTRATHECAL USE WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning. Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ULTRAVIST is not approved for intrathecal use. (5.1)
What it is approved for
From the label in effect Mar 2, 2026.
ULTRAVIST ® Injection is an iodinated contrast agent indicated for: ULTRAVIST is a radiographic contrast agent indicated for: Intra-Arterial Procedures † • Cerebral arteriography and peripheral arteriography in adults ( 1.1 ) • Coronary arteriography and left ventriculography, visceral angiography, and aortography in adults ( 1.1 ) • Radiographic evaluation of cardiac chambers and related arteries in pediatric patients aged 2 years and older ( 1.1 ) Intravenous Procedures † • Excretory urography in adults and pediatric patients aged 2 years and older ( 1.2 ) • Contrast computed tomography (CT) of head and body in adults and pediatric patients aged 2 years and older ( 1.2 ) • Contrast mammography in adults as an adjunct following mammography and/or ultrasound ( 1.2 ) † Specific concentrations and presentations are recommended for each type of imaging procedure. ( 2.2 , 2.3 , 2.4 ) 1.1 Intra-Arterial Procedures* ULTRAVIST is indicated for: • Cerebral arteriography and peripheral arteriography in adults • Coronary arteriography and left ventriculography, visceral angiography, and aortography in adults • Radiographic evaluation of cardiac chambers and related arteries in pediatric patients aged 2 years and older 1.2 Intravenous Procedures* ULTRAVIST is indicated for: • Excretory urography in adults and pediatric patients aged 2 years and older • Contrast Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal, and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults and pediatric patients aged 2 years and older • Contrast mammography to visualize known or suspected lesions of the breast in adults, as an adjunct following mammography and/or ultrasound † Specific concentrations and presentations of ULTRAVIST are...
Mechanism: Intravascular injection of iopromide opacifies those vessels where the contrast agent is present, permitting radiographic visualization of the internal structures through attenuation of photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted blood-brain barrier, contrast agent accumulates in the extravascular space in the region of disruption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 25, 2023 Supplement 54 · Efficacy LetterLabel
- Dec 30, 2009 Supplement 33 · Efficacy LabelLetter
- Jul 23, 1997 Supplement 2 · Efficacy
- May 10, 1995 Original approval · Type 1 - New Molecular Entity
5 products under this application
- ULTRAVIST 150 · IOPROMIDE 31.2% · INJECTABLE, INJECTION · Discontinued
- ULTRAVIST 300 · IOPROMIDE 62.3% · INJECTABLE, INJECTION · Prescription
- ULTRAVIST 300 IN PLASTIC CONTAINER · IOPROMIDE 62.3% · INJECTABLE, INJECTION · Discontinued
- ULTRAVIST 240 · IOPROMIDE 49.9% · INJECTABLE, INJECTION · Discontinued
- ULTRAVIST 370 · IOPROMIDE 76.9% · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Iopromide" as an intervention, any sponsor and status, largest first.
- A Safety Comparison of Iopromide and Iodixanol in Renal Impaired PatientsPivotal-lookingCompleted
Chinese PLA General HospitalAcademic, hospital or other
NCT00926562 · 592 participants · Start Feb 2009 · Primary completion Dec 2010
Drug: Iopromide (Ultravist); Iodixanol (Visipaque) · For: Kidney Failure, Chronic
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 19 sites in all
- Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT AngiographyPivotal-lookingCompleted
GuerbetIndustry
NCT01255722 · 468 participants · Start Nov 2010 · Primary completion Sep 2012
Drug: iobitridol; iopromide and 1 more · For: Coronary Artery Disease
Sites: Angers, France; Brest, France; Le Plessis-Robinson, France · 23 sites in all
- Ultravist: Safety and Efficacy in Computed Tomography of Head and BodyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00244140 · 435 participants · Start Oct 2005 · Primary completion Apr 2008
Drug: Iopromide 370 mg I/mL; Iopromide 300 mg I/mL · For: Computed Tomography; Diagnostic Imaging
Sites: Tucson, Arizona; Miami, Florida; Tallahassee, Florida · 23 sites in all
- Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)Pivotal-lookingCompleted
Ospedale San DonatoAcademic, hospital or other
NCT00827788 · 432 participants (planned) · Start Dec 2008 · Primary completion Apr 2010
Drug: Iodixanol; Iopromide · For: Contrast Induced Nephropathy; Acute Myocardial Infarction
Sites: Arezzo, Italy
- Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus IopromidePivotal-lookingCompleted
Seoul National University Bundang HospitalAcademic, hospital or other
NCT00823628 · 420 participants (planned) · Start Feb 2009 · Primary completion May 2010
Drug: contrast agent (iopromide); contrast agent (iodixanol) · For: Chronic Renal Insufficiency; Coronary Angiography
Sites: Seongnam-si, South Korea
- Renal Toxicity of Iodixanol and Iopromide in Patients With Renal DysfunctionPivotal-lookingStatus unknown
Yong HuoAcademic, hospital or other
NCT01580046 · 200 participants (planned) · Start Apr 2012 · Primary completion Dec 2013
Drug: iodixanol; iopromide · For: Kidney Failure, Chronic
Sites: Hefei, China; Beijing, China; Fuzhou, China · 19 sites in all
GE HealthcareIndustry
NCT03631771 · 0 participants · Start Mar 2022 · Primary completion Aug 2024
Drug: Iohexol; Iodixanol and 2 more · For: Hypothyroidism
GE HealthcareIndustry
NCT00335101 · 0 participants · Start Jun 2006
Drug: Iodixanol, Ioversol, Iopromide · For: Coronary Artery Disease (CAD); Renal Impairment; Diabetes Mellitus
Sites: Princeton, New Jersey; Munich, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea621
- urticaria545
- pruritus481
- erythema394
- anaphylactic shock389
- blood pressure decreased376
- nausea320
- vomiting293
- loss of consciousness255
- oxygen saturation decreased248
- dizziness230
- rash228
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 7 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 13 |
| 2009 | 29 |
| 2010 | 15 |
| 2011 | 17 |
| 2012 | 103 |
| 2013 | 194 |
| 2014 | 208 |
| 2015 | 231 |
| 2016 | 239 |
| 2017 | 203 |
| 2018 | 229 |
| 2019 | 198 |
| 2020 | 282 |
| 2021 | 176 |
| 2022 | 279 |
| 2023 | 413 |
| 2024 | 493 |
| 2025 | 456 |
| 2026 | 392 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Enhanced external counterpulsation: A new method to alleviate contrast-induced acute kidney injury.
Zhang X, Yao C, Xiao Q, et al. · Contemp Clin Trials 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Iopromide and Iodixanol in the Development of Postoperative Contrast Nephropathy in Patients with Renal Insufficiency: A Meta-Analysis.
Feng Y, Qiu G, Xu C, et al. · J Healthc Eng 2022 · Meta-Analysis, Retracted Publication
- Comparative long-term efficacy and safety of two paclitaxel-coated balloons with different coating strategies for the treatment of drug-eluting coronary stent restenosis.
Koch T, Lenz T, Rheude T, et al. · Catheter Cardiovasc Interv 2024 · Comparative Study, Multicenter Study
- [Plasma histamine liberation after the application of nonionic contrast media].
Weiss HD, Jansen O, Schallock J, et al. · Rofo 1989 · Clinical Trial, Comparative Study
- Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
Zhang J, Jiang Y, Rui Q, et al. · Medicine (Baltimore) 2018 · Meta-Analysis, Review
- Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis.
Suh YJ, Yoon SH, Hong H, et al. · Invest Radiol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Bayer · Also marketed as Ultravist 300, Ultravist 300 In Plastic Container, Ultravist 240, Ultravist 370
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.